Compare Stocks → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASLNNASDAQ:CNCENASDAQ:COCPNASDAQ:IFRXNASDAQ:SIOX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.53+8.9%$0.61$0.39▼$4.69$8.74M1.45867,753 shs189,504 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ACOCPCocrystal Pharma$1.49+4.3%$1.49$1.33▼$3.29$15.17M1.3413,716 shs2,106 shsIFRXInflaRx$1.30+2.8%$1.57$1.14▼$5.20$76.54M1.27245,496 shs90,929 shsSIOXSio Gene Therapies$0.48+1.7%$0.46$0.25▼$0.50N/A1.14N/A40,400 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals-0.14%-7.55%-38.59%-7.29%-86.73%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%COCPCocrystal Pharma-2.05%-8.92%-3.38%-7.74%-44.49%IFRXInflaRx-3.44%-16.78%-15.67%-20.94%-70.17%SIOXSio Gene Therapies0.00%0.00%0.00%+22.63%+19.17%[Urgent!] Generational Wealth Gameplan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN Pharmaceuticals2.7938 of 5 stars3.55.00.00.01.60.81.3CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma2.5226 of 5 stars3.53.00.00.00.01.71.3IFRXInflaRx2.5722 of 5 stars3.83.00.00.01.41.71.3SIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals3.00Buy$11.332,019.17% UpsideCNCEConcert PharmaceuticalsN/AN/AN/AN/ACOCPCocrystal Pharma3.00Buy$10.00570.29% UpsideIFRXInflaRx3.50Strong Buy$13.50938.46% UpsideSIOXSio Gene TherapiesN/AN/AN/AN/ACurrent Analyst RatingsLatest CNCE, SIOX, IFRX, ASLN, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.73N/AN/A$0.60 per share0.89CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AIFRXInflaRx$70K1,093.49N/AN/A$1.89 per share0.69SIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$2.74N/AN/AN/AN/A-862.59%-82.83%4/26/2024 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ACOCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)IFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)SIOXSio Gene Therapies-$71.89MN/A0.00∞N/AN/AN/AN/AN/ALatest CNCE, SIOX, IFRX, ASLN, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/A3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A2.112.11CNCEConcert PharmaceuticalsN/A9.039.03COCPCocrystal PharmaN/A8.928.92IFRXInflaRxN/A6.505.82SIOXSio Gene TherapiesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%CNCEConcert Pharmaceuticals70.63%COCPCocrystal Pharma6.72%IFRXInflaRx42.39%SIOXSio Gene TherapiesN/AInsider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%CNCEConcert Pharmaceuticals11.33%COCPCocrystal Pharma25.06%IFRXInflaRx16.30%SIOXSio Gene Therapies3.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals3416.35 million15.58 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableIFRXInflaRx6258.88 million49.29 millionOptionableSIOXSio Gene Therapies12N/AN/ANo DataCNCE, SIOX, IFRX, ASLN, and COCP HeadlinesSourceHeadlineGene Therapy for Parkinson's Diseasemedscape.com - March 31 at 1:50 AMSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Sharefinance.yahoo.com - February 2 at 7:47 AMSio Gene Therapies Inc SIOXmorningstar.com - November 22 at 2:04 PMTwo Promising Gene Therapy Stocks Tackling Eye Diseasethestreet.com - November 1 at 5:29 PMGene Therapy News and Researchnews-medical.net - October 28 at 10:40 AMGene Therapy for Erectile Dysfunctionmedscape.com - October 23 at 7:00 PMIn Mice, Gene Therapy Helps Restore Movement After Spinal Cord Injurysiouxcityjournal.com - September 27 at 3:06 PMRetroviral Vectors for Gene Therapymedscape.com - September 18 at 4:21 PMSio Gene Therapies (NASDAQ: AXGT)fool.com - July 19 at 2:34 AMRoivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billionfinance.yahoo.com - July 13 at 7:44 PMGene Therapy in a Patient with Sickle Cell Diseasenejm.org - June 20 at 10:04 PMGene Therapy for Rheumatoid Arthritismedscape.com - June 12 at 11:10 PMA gene therapy shot might keep cats from getting pregnant without being spayedsciencenews.org - June 12 at 6:10 PMA new gene therapy could be a game-changer for patients with severe anemia. The cost? $2.8 million.nbcnews.com - May 23 at 4:21 PMSio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Resultsfinance.yahoo.com - February 14 at 8:17 AMSIOX Sio Gene Therapies Inc.seekingalpha.com - January 26 at 5:44 PMSio Gene Therapies to dissolve after years of setbacksbiopharmadive.com - December 15 at 2:28 PMSio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolutionfinance.yahoo.com - December 14 at 6:35 PMFollowing layoffs, gene therapy firm leaves Durhambizjournals.com - November 10 at 3:59 PMSio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Resultsfinance.yahoo.com - November 10 at 7:26 AMSio Gene Therapies (NASDAQ:SIOX) Will Have To Spend Its Cash Wiselyfinance.yahoo.com - October 31 at 1:26 PMSio Gene Therapies Announces Fiscal First Quarter 2022 Financial Resultsfinance.yahoo.com - August 11 at 5:41 PMSio Gene Therapies Inc. (SIOX)uk.finance.yahoo.com - August 5 at 9:37 PMGene therapy firm in Durham slashes headcount as biotech stumblesbizjournals.com - June 14 at 6:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Sio Gene TherapiesNASDAQ:SIOXSio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.